ClinicalTrials.gg
RecruitingNCT06947941Updated Jun 30, 2026

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

A Phase 3 interventional study of KarXT and KarX-EC in Alzheimer Disease and Psychosis, sponsored by Bristol-Myers Squibb. Recruiting at 22 sites in 5 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing xanomeline in Alzheimer Disease — 10 open to participants now, 10 under way, 10 of them phase 3. xanomeline · Alzheimer Disease.

Planned enrollment
10th of 10
325 · median 463
Started
2026
the only one that year
Phase 3
10 of 10
10 open now
Registered
6th of 10
by date
Lead sponsor
6 of 10
Bristol-Myers Squibb

Among the 10 studies testing xanomeline in Alzheimer Disease, this one is the 10th largest by planned enrollment, is the only one that started in 2026, is one of 10 in phase 3, and was the 6th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

10 of the 10 studies testing xanomeline in Alzheimer Disease are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing xanomeline in Alzheimer Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.

03

Conditions studied

  • Alzheimer Disease
  • Psychosis

Keywords

  • Alzheimer disease
  • Alzheimer's disease
  • Alzheimer's
  • Dementia
  • Psychosis
  • Alzheimer's disease psychosis
  • Alzheimer's disease psychosis with or without agitation
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 55 to 90 years of age, inclusive, at the time of Screening (Visit 1).
  • Participants must be diagnosed with Alzheimer's disease in accordance with the 2024 revised criteria for diagnosis and staging of Alzheimer's Disease: Alzheimer's Association Workgroup.
  • Participants must have a magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain (completed within the past 5 years) taken during or subsequent to the onset of dementia to rule out other central nervous system (CNS) disease that could account for the dementia syndrome, eg, major stroke, neoplasm, subdural hematoma.
  • Participants must have a history of psychotic symptoms (meeting International Psychogeriatric Association criteria) for at least 2 months prior to Screening (Visit 1) (participants may or may not have symptoms of agitation).

Exclusion criteria

Exclusion Criteria:

  • Participants must not have psychotic symptoms that are primarily attributable to a condition other than the AD causing the dementia, eg, schizophrenia, schizoaffective disorder, delusional disorder, or mood disorder with psychotic features.
  • Participants must not have history of major depressive episode with psychotic features during the 12 months prior to Screening, or history of bipolar disorder, schizophrenia, or schizoaffective disorder.
  • Participants must not have certain safety concerns, including certain laboratory test irregularities.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
325 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Drug: KarXT + KarX-EC Arm Matching Placebo

  • Experimental
    KarXT + KarX-EC Arm

    Drug: KarXT · Drug: KarX-EC

Interventions

  • DrugKarXT

    Drug pages: Xanomeline · Trospium

    Specified dose on specified days

    Also known as: BMS-986510, Xanomeline/Trospium Chloride

  • Specified dose on specified days

    Also known as: BMS-986519, Xanomeline Enteric-coated

  • DrugKarXT + KarX-EC Arm Matching Placebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C: H+D) Score

    Time frame: Up to approximately Week 14

Secondary outcomes

  1. Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score

    Time frame: Up to approximately Week 14

  2. Change From Baseline in Neuropsychiatric Inventory-Clinician Rating Scale (NPI-C) Core Score

    NPI-C Core Score includes assessment for hallucinations, delusions, agitation, and aggression domains

    Time frame: Up to approximately Week 14

  3. Change From Baseline in NPI-C: Agitation Score

    Time frame: Up to approximately Week 14

  4. Change From Baseline in NPI-C Core Score: Caregiver Distress Scale

    NPI-C Core Score: Caregiver Distress Scale includes assessment for hallucinations, delusions, agitation, and aggression domains

    Time frame: Up to approximately Week 14

  5. Responder Rate

    Responder rate is defined as improvement from baseline in NPI-C: H+D score ≥ 40%.

    Time frame: Up to approximately Week 14

  6. Change From Baseline in Cohen-Mansfield Agitation Inventory International Psychogeriatric Association (CMAI-IPA) Score

    Time frame: Up to approximately Week 14

  7. Change From Baseline in CMAI Total Score

    Time frame: Up to approximately Week 14

  8. Number of Participants With Adverse Events (AEs)

    Time frame: Up to approximately Week 14

  9. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to approximately Week 14

  10. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Up to approximately Week 14

  11. Number of Participants With TEAEs Leading to Discontinuation

    Time frame: Up to approximately Week 14

  12. Number of Participants With Spontaneously Reported Procholinergic Symptoms

    Procholinergic symptoms include nausea, vomiting, and diarrhea.

    Time frame: Up to approximately Week 14

  13. Number of Participants With Spontaneously Reported Anticholinergic Symptoms

    Anticholinergic symptoms include dry mouth, constipation, urinary retention and blurred vision.

    Time frame: Up to approximately Week 14

  14. Number of Participants With AEs of Special Interest (AESIs)

    AESIs such as symptomatic orthostasis, syncope, urinary adverse events, and elevated liver enzymes will be evaluated.

    Time frame: Up to approximately Week 14

  15. Barnes Akathisia Rating Scale (BARS) Score

    Time frame: Up to approximately Week 14

  16. Abnormal Involuntary Movement Scale (AIMS) Score

    Time frame: Up to approximately Week 14

  17. International Prostate Symptom Score (IPSS)

    This will be measured in males only.

    Time frame: Up to approximately Week 14

  18. Body Weight

    Time frame: Up to approximately Week 14

  19. Body Mass Index (BMI)

    Time frame: Up to approximately Week 14

  20. Number of Participants With Clinically Significant Changes in Orthostatic Vital Sign: Blood Pressure (BP)

    This includes measuring of BP, supine or sitting and then standing after approximately 2 minutes, no later than approximately 3 minutes.

    Time frame: Up to approximately Week 14

  21. Number of Participants With Clinically Significant Changes in Orthostatic Vital Sign: Heart Rate (HR)

    This includes measuring of HR, supine or sitting and then standing after approximately 2 minutes, no later than approximately 3 minutes.

    Time frame: Up to approximately Week 14

  22. Number of Participants With Clinically Significant Changes in Laboratory Evaluations: Hematology

    Time frame: Up to approximately Week 14

  23. Number of Participants With Clinically Significant Changes in Laboratory Evaluations: Clinical Chemistry

    Time frame: Up to approximately Week 14

  24. Number of Participants With Clinically Significant Changes in Laboratory Evaluations: Coagulation Parameters

    Time frame: Up to approximately Week 14

  25. Number of Participants With Clinically Significant Changes in Laboratory Evaluations: Prolactin Levels

    Time frame: Up to approximately Week 14

  26. Number of Participants With Clinically Significant Changes in Laboratory Evaluations: Urinalysis

    Time frame: Up to approximately Week 14

  27. Number of Participants With Clinically Significant Changes in Laboratory Evaluations: Drug Screening

    Time frame: Up to approximately Week 14

  28. Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG)

    Time frame: Up to approximately Week 14

  29. Number of Participants With Suicidal Ideations and Behavior as Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to approximately Week 14

  30. Number of Participants With Cognitive Impairment as Assessed by Mini-mental State Examination (MMSE)

    Time frame: Up to approximately Week 14

  31. Number of Participants With Cognitive Impairment as Assessed by 13-item Variation of ADAS-Cog Scale (ADAS-Cog-13)

    Time frame: Up to approximately Week 14

07

Study locations

3 of 22 sites recruiting
  • Gilbert Neurology Partners/CCT Research
    Gilbert, Arizona 85297, United States
    Recruiting
    • Jonathan Hodgson, Site 0042 · Contact602-761-9631
  • Inland Psychiatric Medical Group.
    Chino, California 91710, United States
    Recruiting
    • Nandita Puchakayala, Site 0031 · Contact909-488-9116
  • Local Institution - 0001
    Naples, Florida 34105, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1401
    Naples, Florida 34105, United States
    Not yet recruiting
    • Site 1401 · Contact
  • Local Institution - 0029
    Cleveland, Ohio 44195, United States
    Not yet recruiting
    • Site 0029 · Contact
  • Insight Clinical Trials LLC - Independence
    Independence, Ohio 44131, United States
    Recruiting
    • Mark Stillman, Site 0043 · Contact216-444-8897
  • Local Institution - 0020
    Macquarie Park, New South Wales 2113, Australia
    Not yet recruiting
    • Site 0020 · Contact
  • Local Institution - 0052
    Nedlands, Western Australia 6009, Australia
    Not yet recruiting
    • Site 0052 · Contact
  • Local Institution - 0054
    Toronto, Ontario M6J1H4, Canada
    Not yet recruiting
    • Site 0054 · Contact
  • Local Institution - 0027
    Whitby, Ontario L1N 5S9, Canada
    Not yet recruiting
    • Site 0027 · Contact
  • Local Institution - 0025
    Montreal, Quebec H4H 1R3, Canada
    Not yet recruiting
    • Site 0025 · Contact
  • Local Institution - 0040
    Suita, Osaka 565-0871, Japan
    Not yet recruiting
    • Site 0040 · Contact
  • Local Institution - 0035
    Nankoku-shi, 783-8505, Japan
    Not yet recruiting
    • Site 0035 · Contact
  • Local Institution - 0034
    Osaka, 550-0006, Japan
    Not yet recruiting
    • Site 0034 · Contact
  • Local Institution - 0005
    Exeter, Devon EX12LU, United Kingdom
    Not yet recruiting
    • Site 0005 · Contact
  • Local Institution - 0023
    London, England W1G 8TA, United Kingdom
    Not yet recruiting
    • Site 0023 · Contact
  • Local Institution - 0015
    Oxford, Oxfordshire OX3 7JX, United Kingdom
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0009
    Chertsey, Surrey KT160PZ, United Kingdom
    Not yet recruiting
    • Site 0009 · Contact
  • Local Institution - 0017
    Sheffield, Yorkshire and the Humber S47QQ, United Kingdom
    Not yet recruiting
    • Site 0017 · Contact
  • Local Institution - 0018
    Crowborough, TN6 1NY, United Kingdom
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0024
    London, WC1N3BG, United Kingdom
    Not yet recruiting
    • Site 0024 · Contact
  • Local Institution - 0004
    Motherwell, ML1 4UF, United Kingdom
    Not yet recruiting
    • Site 0004 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2028, 22 months after the start.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 22 months is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2025
First posted
Apr 27, 2025
StartActual
Mar 25, 2026
Primary completionEst.
Feb 21, 2028
CompletionEst.
Mar 20, 2028
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06947941
Responsible party
Sponsor
First posted
Apr 27, 2025
Start date
Mar 25, 2026
Primary completion
Feb 21, 2028 (estimated)
Completion
Mar 20, 2028 (estimated)
Last update
Jun 30, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com, www.BMSStudyConnect.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium

Start the discussion